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Ibuprofen is a propionic acid derivative that belongs to the class NSAIDs. Major adverse reactions 
associated with Ibuprofen are related to GIT and include peptic and mucosal ulcers, dyspepsia, severe 
gastric pain and bleeding, that results in excessive treatment failure. The goal of this study was to 
develop enteric coated ibuprofen tablets in order to avoid gastric mucosal irritation, diffusion of drug 
across mucosal lining and to let active ingredient be absorbed easily in small intestine. The formulation 
was developed and manufactured through the direct compression process, the simplest, easiest and most 
economical method of manufacturing. Enteric coating was done using an Opadry white subcoating and 
an aqueous coating dispersion of Acryl-Eze. Enteric coated formulation was subjected to disintegration 
and dissolution tests by placing in 0.1 M hydrochloric acid for 2 h and then 1 h in phosphate buffer with 
a pH of 6.8. About 0.04% of drug was released in the acidic phase and 99.05% in the basic medium. 
These results reflect that ibuprofen can be successfully enteric coated in order to prevent its release in the 
stomach and facilitate rapid release of the drug in the duodenum, due to the presence of superdisintegrant. 
Formulating this enteric coated tablets could increase patient compliance by decreasing adverse drug 
reactions (ADR
S
) associated with Ibuprofen therapy.
Uniterms: Ibuprofen/adverse reactions. Tablets/enteric coating/aqueous dispersion system. Acryl-Eze. 
Opadry White. Superdisintegrant.
Ibuprofeno é um derivado do ácido propiônico, que pertence à classe dos fármacos não-esteróides 
(AINES). As principais reações adversas associadas com o ibuprofeno se referem àquelas do trato 
gastrintestinal (TGI), como úlceras pépticas e da mucosa, dispepsia, dor gástrica grave e sangramento, que 
resultam em muitas falhas de tratamento. O objetivo do estudo foi desenvolver comprimidos revestidos 
de ibuprofeno que impeçam a irritação da mucosa gástrica, difusão do fármaco através da mucosa e 
permitam, facilmente, a absorção do princípio ativo do intestino delgado. A formulação foi desenvolvida 
e manufaturada por meio de processo de compressão direta, método mais simples e econômico de 
preparação. O revestimento entérico foi efetuado utilizando-se subrevestimento com Opadry branco e 
revestimento por dispersão aquosa de Acryl-Eze. A formulação de revestimento para liberação entérica 
foi submetida a testes de desintegração e de dissolução, em ácido clorídrico 0,1 M, por 2 h, e, então, 
a h, em tampão fosfato pH 6,8. Cerca de 0,04% do fármaco foi liberado na fase ácida e 99,05%, no 
meio básico. Estes resultados refletem o fato de que o ibuprofeno pode ser revestido com sucesso, a 
fim de impedir sua liberação no estômago e facilitar a rápida liberação do fármaco no duodeno, devido 
à presença de superdesintegrante. A formulação de tais comprimidos aumentaria a adesão do paciente 
pela diminuição das reações adversas (RAs), associadas à terapia com ibuprofeno.
Unitermos: Ibuprofeno/reações adversas. Comprimidos/revestimento entérico/sistema de dispersão 
aquosa. Acryl-Eze. Opadry Branco. Superdesintegrante.
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INTRODUCTION
The application of coatings to the surface of phar-
maceutical solid-dosage forms, especially tablets, has 
been practiced for over 150 years (Porter, Bruno, 1990). 
A significant proportion of pharmaceutical solid dosage 
forms are coated to give an esthetic touch and to control 
the bioavailability of the drug (Porter, 2000). Film coating 
is a technique widely used in the pharmaceutical field to 
improve and modify technological and release characteris-
tics of capsules, tablets and granules due to the capability 
of depositing a variety of coating materials onto solid 
cores (Bonacucina et al., 2006; Fitzgerald, Cole, Taday, 
2005, Nastruzzi et al., 2000; Cole et al., 2002; Bobmeir, 
1997). The particles prepared by film-coating show the 
best stability (Wieland-Berghausen et al., 2002). Tablet 
size, shape and coating are pharmaceutical parameters 
which can be controlled to minimize esophageal contact 
of a dosage form with esophageal tissue (Perkins et al., 
2001). For instance, enteric coating of acetyl salicylic acid 
tablets is desirable for preventing stomach upset or irrita-
tion in patients taking daily doses (Cunningham, Kinsey, 
Scattergood, 2001).
Enteric polymers have been shown to be safe, and 
widely accepted for use in drug products (Biju et al., 
2004; Nykanen, 2003). These polymers are insoluble at 
low pH but dissolve at a pH around or below 7 (Peeters, 
Kinget, 1993; Bauer, Kesselhut, 1995; Hogan, 1995). A 
number of coating polymers are available commercially. 
Shellac is a natural enteric polymer which results in good 
gastric resistance; however, it often dissolves too slowly in 
intestinal fluids (Pearnchob, Dashevsky, Bodmeir, 2004). 
Hydroxypropyl methylcellulose (HPMC) was selected as 
a base polymer to develop novel enteric coating agents 
for acid protection, in contrast to ethyl cellulose (EC), it is 
water soluble and might leach out of the film coating, cre-
ating water filled pores through which drug diffuses more 
rapidly than EC (Kokubo et al., 1997; Gunder, Lippold, 
Lippold, 1995). Acryl-Eze is a pre-mixed excipient blend 
based on a methacrylic acid copolymer that is optimized 
for film-coating applications (Young et al., 2005).
A continuing trend in pharmaceutical coating te-
chnology is to use water instead of organic solvents as 
coating vehicles to minimize environmental and safety 
hazards. Several aqueous enteric coating systems have 
been developed and are commercially available (Yuan, 
Clipse, Wu, 2003). Aqueous-based coating systems are ad-
vantageous over organic solvents because they overcome 
the drawbacks of the latter, namely pollution, explosion 
hazards and solvent toxicity, especially for operators. For, 
these reasons, water-based systems are now gradually 
being applied instead of organic coating systems (Bau-
doux, Dechesne, Delattre, 1990). The coating material is 
added as an aqueous solution or dispersion and the excess 
liquid phase must then be removed, usually by hot air 
(Lund, 1994). Although aqueous enteric coating systems 
were an advance on traditional solvent systems, they requi-
re separate addition of plasticizers, detackifiers, pigments 
and other process aids (Lechmann, 1982). Multiple, time-
consuming steps are required in the preparation of these 
aqueous enteric coating dispersions. In addition, many of 
theses systems are provided as liquid dispersions, which 
can be problematic when handling, transporting and con-
trolling storage conditions (Cunningham, Fegley, 2001).
The model drug is ibuprofen, a widely used NSAI-
Ds. It is an analgesic, anti-inflammatory and anti-pyretic 
agent (Nazu, 1978; Wood et al., 2006; Potthast et al.,, 
2005). NSAIDs are a group of unrelated organic acids 
that mostly affect GIT. Dyspeptic complaints (Hollenz , 
Labenz, 2004) , upper GI bleeding (Blot et al., 2004) and 
mucosal and duodenal ulcers (Davis, 1999; Rang, Dale, 
Ritter, 2003; Ross, DeHoratius, 1990) are common ADRs 
associated with this group and may be life threatening 
(Motola et al., 2004). In 2002, Aletaha found that about 
72% of the patients with rheumatoid arthritis treated with 
NSAIDs received GI-protective therapy mainly with 
histamine antagonists and sucralfalate (Aletaha, Smolen, 
2002). Due to GI side effects, the health and economic bur-
dens related to these drugs are considerable (Schwappach, 
Koeck, 2003). A distinct relationship between effects and 
side effects exists, namely, rapid absorption beginning in 
the stomach is associated with intensive gastric-duodenal 
irritation and ulceration (Brune, Beck,1991). Epidemio-
logical studies have clearly demonstrated a rank order of 
risk of ulcer complications for commonly used NSAIDs, 
with ibuprofen consistently associated with the lowest risk, 
and piroxicam with the highest (Wolfe, 2003; Langman, 
2003).
The aim of current investigation was to develop en-
teric coated ibuprofen tablets (200 mg) using an aqueous 
Opadry/Acryl-Eze system, resulting in protection against 
gastric ADRs. This study evaluated both systems for ease 
of use and acid resistance. Stability of coated tablets was 
determined at room and under accelerated conditions.
MATERIALS AND METHOD
Materials
Pure Ibuprofen pure was donated by Deluxe Phar-
ma, Pakistan, Microcrystalline Cellulose (Avicel PH-101; 
FMC Corporation, USA), Crospovidone (ISP Techno-
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logies, Inc. Wayne, NJ) and Magnesium Stearate (FMC 
Corporation, USA) were used as directly compressible 
excipients. Sodium hydroxide (Merck, Kga A, and Darms-
tadt, Germany); Monobasic Potassium Phosphate (Merck, 
Kga A, and Darmstadt, Germany); Methanol HPLC grade 
(RDH, Sigma-Aldrich GmbH, Seelze, Germany) and all 
other chemicals used were of analytical grade and obtained 
from commercial sources. The enteric coating materials 
were methacrylic acid polymer based pigmented Acryl-
Eze (93092157) yellow and the sub coat material was 
Opadry (YS-1-7027) white, all from Colorcon (Verna, 
Goa, India).
Packaging materials used for the tablet stability test 
were polyvinyl chloride (PVC), 218 mm and aluminium 
foil 206 mm (Zibo Omy Economic and Trading Co. Ltd., 
China). 
Preparation of Tablets
All the ingredients were properly weighed and sie-
ved through a 20 mesh sieve. The blend was compressed 
using a single punch machine (KORSCH Erweka, No. 
7570, Frankfurt, Germany). For optimization, nine di-
fferent formulations of ibuprofen (200 mg) tablets were 
developed (Table I) and on the basis of the results obtained 
from evaluation of different physico-chemical parameters, 
formulation 6 was selected as an optimized formulation 
for enteric coating (Bushra et al., 2008). 
Enteric Coating of Ibuprofen (200 mg) tablets
· Preparation of Opadry White solution
Compressed tablets were sub coated using Opadry 
white dispersion. This was prepared by accurately wei-
ghing 50g of Opadry white formulated powder while 600 
mL of mixture of methyl chloride and ethanol (343 mL of 
methyl chloride and 257 mL of ethanol) (Cole, 1990) was 
utilized as the organic solvent, being stirred continuou-
sly to form a vortex without drawing air into the liquid. 
Opadry white coating powder was added steadily to the 
vortex, avoiding powder flotation on the liquid surface. 
This dispersion was thoroughly mixed for 40- 45 minutes 
in order to obtain a homogenized distribution.
· Preparation of Acryl-Eze Yellow dispersion
320 g of distilled water was weighed into a mixing 
vessel and stirred to form a vortex. 80 g Acryl-Eze yellow 
powder was weighed accurately and added to the center 
of the liquid vortex in a slow steady stream, avoiding 
clumping and maintaining a vortex. Mixing was continued 
for around 20 - 25 minutes. Finally Acryl-Eze dispersion 
was passed through a 250 micron sieve prior to the coating 
process. Dispersion was continuously stirred during the 
coating process. Both coating dispersions were prepared 
according to the technical document and guidelines pro-
vided by Colorcon (Colorcon, 2006).
· Coating methodology
Tablet coating was performed in a conventional 
coating pan (Erweka G.m.b.H., type UG, Frankfurt, 
Germany) with one spray gun. Table II lists the coating 
conditions and parameters. Tablet cores were pre-heated 
to about 40 °C utilizing a dryer and air compressor (Type 
H-2, No. 311319, Meiji air compressor Mfg. Co. Ltd. 
Osaka, Japan). The spray gun was filled with Opadry 
white coating dispersion and operated at a proper flow 
rate. The pan was set into motion and seal coating solution 
TABLE I - Composition of Ibuprofen 200mg tablets (Bushra et al., 2008)
Batch Code
Ingredients (mg/ tablet) F1 F2 F3 F4 F5 F6 F7 F8 F9
Ibuprofen 200 200 200 200 200 200 200 200 200
Avicel PH101 150 150 150 175 200 200 200 175 175
Magnesium Stearate 05 7.5 2.5 05 05 05 05 05 05
Crospovidone 10 10 10 10 10 05 2.5 05 2.5
Quantity per Tablet (mg) 365 367.5 362.5 390 415 410 407.5 385 382.5
TABLE II - Coating Process Parameters
Factors Conditions
Equipment 12 inch coating pan
Substrate 200-mg Ibuprofen tablets
Pan charge 1 kg
Inlet Temperature 55-65 °C
Bed Temperature 35-40 °C
Distance between spray 
gun and tablet bed
6 inches
No. of spray guns 1
Pan Speed 12 rpm
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was sprayed on to the falling cores under a suitable air 
pressure (30-35 psi). Upon completion of seal coating, the 
air heater was switched off and tablets were blow dried 
for 20-25 minutes in the coating pan. The spray gun was 
washed thoroughly and filled with prepared Acryl-Eze 
yellow aqueous dispersion and the same procedure was 
followed for final coating. The core tablets gained 2% 
weight during sub coating and about 8-10% weight after 
Acryl-Eze dispersion. (Table III).
Characterization of coated tablets
· Mechanical strength:
The hardness of the coated tablets was examined 
by using a tablet hardness tester (Fujiwara, Seisukusho 
Corporation, Japan). The hardness of 20 randomly selected 
tablets is shown in Figure 1.
· Disintegration Test
The disintegration test was performed according to 
B.P 2004. Six enteric coated tablets were placed in acidic 
phase consisting of 0.1 M hydrochloric acid. The assembly 
was operated without the discs for 2 h in a USP basket rack 
assembly (Erweka ZT-2, Husenstamn). Tablets were re-
moved from solution, dried gently with a paper towel and 
disintegration was continued in buffer phase for 1 h. Buffer 
phase was composed of mixed phosphate buffer with a 
pH of 6.8 that was maintained at 37±2 °C. The assembly 
was removed and tablets were observed for disintegration.
· Dissolution Test
The dissolution testing of enteric coated formulation 
was carried out according to USP 27 NF 22 <711>, by 
adopting Method B (USP convention INC., 2004) in pH 
1.2 and pH 6.8 buffers. 
The Acid Stage was performed using 1000 mL of 
0.1 M hydrochloric acid placed in a USP dissolution bath 
(Erweka DT 700, Husenstamn, Germany), equilibrated to 
a temperature of 37± 0.5 °C. The paddle stirring rate was 
set at 50 rpm. Six tablets were introduced into the appara-
tus and the apparatus was run for 2 h. After the operation 
outlined above, an aliquot of the fluid was drawn, and the 
Buffer Stage was commenced. 
The Buffer Stage consisted of a phosphate buffer of 
pH 6.8 prepared by mixing 0.1 M hydrochloric acid with 
0.20 M tribasic sodium phosphate (3:1). The apparatus was 
operated for a further 1 h. At the end of the time period, 
an aliquot of the fluid was drawn. Samples were assayed 
spectrophotometrically (UV 150-02, Double beam spec-
trophotometer, Shimadzu Corp., Japan) at 221 nm.
Stability test of coated tablets
Ibuprofen coated tablets were blister packed using a 
blister packing machine (BQS, H 060125, Pam-Pac Machi-
nes Pvt. Ltd.) in 1× 10’s using aluminium foil 206 and PVC 
218 mm (Zibo Omy Economic and Trading Co.Ltd., China). 
Stability studies were carried out according to ICH guide-
lines. Tests were conducted under room temperature (RT) 
and accelerated stability conditions. The samples designed 
for RT storage were kept at 30±2 °C and 65±5% relative 
humidity (RH) and for accelerated stability were reserved 
at 40±2 °C and 75±5% RH, in a humidity chamber (Binder 
GMBH Bergster, 14D-78532, Tuttingen Germany). The 
RT samples were pulled from stability and tested 0, 3, 6, 9 
and 12 months after the date of packaging. The accelerated 
stability samples were pulled from stability and tested 0, 1, 
2, 3 and 6 months after the date of packaging. Dissolution 
and assay were performed to evaluate the stability of coa-
ted tablets. The percent dissolution and assay of the coated 
tablets are shown in Tables V and VI.
TABLE III - Dispersion Preparation Parameters
Parameters Sub coat layer Acryl-Eze
Theoretical weight gain (%) 2 8-10
Dispersion solid content (%) 15 20
Powder (g) 30 80
Organic Solvent (mL) 600 N/A
Deionized Water (g) N/A 320
Total Dispersion (mL) 630 400
FIGURE 1 - Mechanical strength of coated tablets, with upper 
and lower control limits.
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RESULTS AND DISCUSSION
Controlled and localized release of drugs in the in-
testine can be achieved by enteric coating. The design of 
enteric-coated tablets has so far remained empirical, in part 
because of the lack of a quantitative description of the drug 
release kinetics (Ozturk et al., 1998; Hosny, El-Mahrouk, 
Gouda, 1998). The functionality of coatings from aqueous 
dispersions is linked to coalescence of latex particles. Thus 
any incomplete film formation, caused by too high or too 
low coating temperatures, may result in highly permeable 
coatings (Petereit,Weisbrod, 1999).
The goal of this study was to develop enteric coated 
ibuprofen tablets. Opadry white coating dispersion was 
used for sub coating. Enteric coating was successfully 
done using Acryl-Eze Yellow polymer which is an aqueous 
dispersion. Tablets were coated smoothly without having 
any physical visible defects such as orange peel effect, 
chipping, tacking or other flaws. These two systems are 
dry, dispersible powders that do not require the use of any 
additional plasticizer, detackifiers or neutralization agents. 
During coating, certain parameters require great care such 
as temperature of coating pan and the spray rate of coating 
solution. If these are not maintained properly, they affect 
the smoothness and uniformity of coating. The hardness 
of 20 coated tablets was measured using a hardness tester 
and were found to be in accordance with specifications. 
Tablet hardness is represented graphically with three upper 
and lower control limits (Figure 1). The efficiency of the 
coating was determined by subjecting the coated tablets 
to gastric pH, and drug release was analyzed by a spectro-
photometer. Results of disintegration and dissolution are 
shown in Tables IV and V.
Krogers et al., in 2002, investigated three formu-
lation or process parameters of potential importance, 
including the plasticizer concentration, the temperature of 
coating pan and the spray rate of the coating solution. At 
low spray rates, the temperature of the coating pan did not 
affect the roughness of the coated tablets. At higher spray 
rates, higher temperature gave smoother films. In another 
study, process variables investigated were inlet airflow, 
pan speed, inlet air temperature, coating time, atomization 
pressure, and fan pressure. Pan speed and coating duration 
were also identified as variables significantly affecting 
content uniformity (Krogars et al., 2000; Rege, Garmise, 
2003). It was shown that lower rates of drug release from 
the coated tablets may be obtained by using high inlet-air 
temperature and low spray rate of the polymeric dispersion 
during coating. Increased temperature for various time 
periods to remove water and solvent from the product 
affects the properties of final products (Frisbee, Metha, 
McGinity, 2002).
Tablets used in a functional coating process must 
be sufficiently robust to withstand mechanical stresses 
and should exhibit a very low potential for erosion and 
edge chipping. Any defect in the tablet core may result in 
a localized weakness of the functional film. A sub coating 
process may be used in order to provide a protective co-
ating to the cores, although this step is optional. Subcoa-
ting does however prevent interaction between the drug 
substance and coating polymer. In this study, sub coating 
was done with Opadry white, resulting in smooth tablets 
with improved mechanical strength. Acryl-Eze Yellow 
and Opadry white dispersions are fully formulated poly-
mer systems, whose mixing process consisted of a simple 
addition of the powder formulations to water. It requires 
little effort and time. Sieving was done to ensure that no 
dispersed particles of polymer remained that could result 
in gun blockages. Both dispersions were stirred during 
the experiment to avoid sedimentation and coalescence 
of particles.
Many authors have described different enteric co-
ated formulations using a variety of coating polymers to 
avoid local gastrointestinal irritation (Debunne, Vervaet, 
Remon, 2002; Biju et al., 2004; Sinha et al., 2006). In 
the current study, Crospovidone, a superdisintegrant, 
was utilized which showed fast in vitro drug release 
and presented better burst effect and rapid drug release 
compared to traditional disintegrants (Tables IV and V). 
This approach is especially important because the release 
of drug is already delayed for 2h, thus by incorporation 
of Crospovidone the drug will be rapidly released in the 
duodenum as the polymer coat erodes at high pH 6-7. Ta-
blets showed complete acid resistance for 2 h (Figure 2). 
Drug release met the criteria outlined in this study i.e. not 
less than 80% dissolved after 60 minutes in buffer pH 6.8. 
Although traditional aqueous enteric coating systems can 
TABLE IV - Disintegration result of ibuprofen (200 mg) tablets
Media Result
0.1 M hydrochloric acid No signs of cracking or 
softening observed
Phosphate Buffer pH 6.8 Tablet was completely 
disintegrated in 7-9 minutes.
TABLE V - Dissolution result of ibuprofen (200mg) tablets
Media Average Drug Release (%)
0.1 M hydrochloric acid 0.08
Phosphate Buffer pH 6.8 99.05
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require multiple component mixing steps before coating, 
these novel systems were dispersed in only one step in the 
minimum amount of time, and produced acceptable weight 
gains. The acrylic-based system offers the additional ad-
vantage of being fully pigmented, eliminating the need for 
additional color application if a colored tablet is desired.
Tablets were stored in a temperature and humidity 
controlled chamber to observe the stability of the formula-
tion. Results of stability testing were satisfactory, showing 
no significant variation in physical characteristics, color, 
hardness or disintegration time of coated tablets. In vitro 
drug release studies were carried out since these are con-
sidered the best tool for assessing in vivo drug behavior. 
Percent dissolution and assay were within the acceptable 
limits of USP (Tables VI and VII). All data indicated that 
the coating layer was essentially unchanged and provided 
the desirable enteric protection. Coated ibuprofen tablets 
were stable under stability testing conditions.
CONCLUSION
The intention was to prepare enteric coated ibu-
profen tablets (200 mg) using a novel Acryl-Eze yellow 
enteric polymer and Opadry white aqueous dispersions 
that prevent drug liberation in the stomach. The coating 
process for both systems was free of problems and resulted 
in highly smooth coated colored tablets with no visible 
defects. Dissolution and disintegration results showed 
strong acid resistance whereas the drug was freely released 
in 6.8 buffer solution. The results of stability testing were 
satisfactory, indicating that coated ibuprofen tablets were 
stable under the testing conditions.
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